Compare
Amgen vs Harmony Biosciences Holdings (AMGN vs HRMY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Harmony Biosciences Holdings (HRMY) +5.6%; so far this year the figures are +40.7% and -11.5%.
Amgen is the larger company by market value, about 128.4 times the size of Harmony Biosciences Holdings.
On trailing earnings, AMGN trades at 26.7 times and HRMY at 10.9 times.
Revenue grew +8.2% at AMGN and +19.8% at HRMY over the last year.
AMGN yields 2.16%. HRMY pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | HRMY | |
|---|---|---|
| Price | $460.42 | $33.11 |
| 1-day | +0.03% | +1.97% |
| YTD | +40.67% | -11.52% |
| 1 year | +43.94% | +5.61% |
| 3 years | +76.51% | +35.03% |
| Market cap | $249.1B | $1.9B |
| P/E | 26.7 | 10.9 |
| P/S | 6.40 | 1.97 |
| P/B | 17.35 | 1.81 |
| Revenue growth | +8.20% | +19.80% |
| EPS growth | +33.30% | -4.70% |
| Gross margin % | 70.9 | 74.0 |
| Net margin % | 24.1 | 18.1 |
| ROE % | 65.4 | 16.7 |
| Debt / equity | 3.76 | 0.14 |
| FCF yield % | 3.8 | 16.6 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.59 |
| RSI (14) | 60.5 | 30.9 |
| Technical rating |